Clinical Trial Update: To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. [Phase 2]

View source ↗

Summary

Clinical trial update announcing a Phase 2 study to evaluate RNK08954 in metastatic pancreatic ductal adenocarcinoma with KRAS G12D mutations; recruitment is on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• RNK08954

Snippet

Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. | Conditions: KRAS G12D Mutations, Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Status: RECRUITING